FDA allows marketing for Affymetrix CytoScan Dx Assay


The FDA clears a first-of-a-kind blood test, developed by Affymetrix (AFFX -0.3%), that can help predict intellectual disabilities in infants by analyzing their genetic code.

The CytoScan Dx Assay test detects variations in patients' chromosomes that are linked to Down syndrome, DiGeorge syndrome and other developmental disorders.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs